Acadia has closed at a new all-time high on a inter-weekly basis. The stock finished the day strong, on above average volume. Below is a weekly chart of ACAD.
Bottom Line: Even though the company announced a short delay for filing their new drug application for Nuplazid, the stock held up well, and has actually advanced higher. Last week, the analyst house Cowen Group, provided coverage on ACAD with a buy rating, and a $46.00 price target on the stock. Perhaps that, and a strong biotech sector has contributed to the new high. Thank you for reading. We currently hold ACAD, and AVNR.
No comments:
Post a Comment